In the latest trading session,, 0.7 million Edwards Lifesciences Corp (NYSE:EW) shares changed hands as the company’s beta touched 1.11. With the company’s most recent per share price at $77.94 changed hands at -$0.1 or -0.13% at last look, the market valuation stands at $45.72B. EW’s current price is a discount, trading about -22.21% off its 52-week high of $95.25. The share price had its 52-week low at $58.93, which suggests the last value was 24.39% up since then. When we look at Edwards Lifesciences Corp’s average trading volume, we note the 10-day average is 4.46 million shares, with the 3-month average coming to 4.78 million.
Analysts gave the Edwards Lifesciences Corp (EW) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.16. If we narrow down to specifics, the data shows that 1 out of 17 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended EW as a Hold, 14 felt it is a Buy and 0 rated the stock as Underweight. Edwards Lifesciences Corp’s EPS for the current quarter is expected to be 0.62.
Edwards Lifesciences Corp (NYSE:EW) trade information
Instantly EW was in red as seen in intraday trades today. With action 3.23%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 5.28%, with the 5-day performance at 3.23% in the green. However, in the 30-day time frame, Edwards Lifesciences Corp (NYSE:EW) is 12.63% up. Looking at the short shares, we see there were 8.24 million shares sold at short interest cover period of 1.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 76.5, meaning bulls need a downside of -1.88% from its recent market value. According to analyst projections, EW’s forecast low is 74 with 90 as the target high. To hit the forecast high, the stock’s price needs a -15.47% plunge from its current level, while the stock would need to tank 5.06% for it to hit the projected low.
Edwards Lifesciences Corp (EW) estimates and forecasts
Year-over-year growth is forecast to reach 8.27% up from the last financial year.
Consensus estimates given by 26 financial analysts project the company’s revenue in the current quarter to hit an average of 1.48B. 24 analysts are of the opinion that Edwards Lifesciences Corp’s revenue for the current quarter will be 1.47B. The company’s revenue for the corresponding quarters a year ago was 1.63B and 1.35B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -9.08%. The estimates for the next quarter sales put growth at 8.79%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.36%. The 2025 estimates are for Edwards Lifesciences Corp earnings to increase by 1.59%, but the outlook for the next 5-year period is at 8.55% per year.
EW Dividends
Edwards Lifesciences Corp is expected to release its next quarterly earnings report on 2025-Apr-22.
Edwards Lifesciences Corp (NYSE:EW)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.92% of Edwards Lifesciences Corp shares while 89.77% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 90.61%. There are 89.77% institutions holding the Edwards Lifesciences Corp stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 8.8982% of the shares, roughly 53.58 million EW shares worth $4.95 billion.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.4663% or 50.98 million shares worth $4.71 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund . With 18.49 shares estimated at $1.44 billion under it, the former controlled 3.15% of total outstanding shares. On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund held about 3.14% of the shares, roughly 18.39 shares worth around $1.44 billion.
